Crinetics Pharmaceuticals, Inc. (CRNX) — Analysis Summary
Crinetics Pharmaceuticals, Inc. (CRNX) has a market cap of $8.84B with year-over-year revenue growth of +640.7%. Net margin stands at -6046.2%. The stock trades at a P/E ratio of -17.8.
Key Takeaways
- Revenue changed +640.7% year-over-year
- Net margin of -6046.2%
- P/E ratio of -17.8
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, CRNX posted revenue growth of +640.7% and trades at a P/E of -17.8.
Crinetics Pharmaceuticals, Inc. (CRNX)
UPDATED — ET · SOURCE POLYGON
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Operating margin at -3020.3% — severe operating losses
Net margin at -2747.2% — losses exceed revenue (possible one-time charges)
The latest filing shows negative free cash flow.
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
Sector
PHARMACEUTICAL PREPARATIONS
Employees
594
Headquarters
SAN DIEGO, CA
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.